Local view for "http://purl.org/linkedpolitics/eu/plenary/2001-10-04-Speech-4-190"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20011004.9.4-190"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
". – The problem raised by the patents granted by the European Patent Office to Myriad Genetics does not appear to derive from the field of ethics. These patents highlight a technical question deriving from the field of patent law. The situation is thus completely different from that raised by the famous "Edinburgh patent".
The problem resides more in the extent of the protection to be granted to these patents. This question is highly complex since, as it applies to gene sequences, it undoubtedly involves a situation relating to competition and innovation, and in no way fundamental principles relating to the dignity or integrity of human beings. It should be noted that this patent is of undoubted interest for the scientific community. It should make it possible to improve the early detection of breast cancer in women.
The Commission considers there are no imperative reasons why the Commission should raise any objections, as the contested patent does not infringe essential ethical rules and concerns the field of application which can be granted to a patent relating to a DNA sequence. Nevertheless, the Commission will study the question of the field of protection for inventions relating to gene sequences in depth and will communicate its observations to the Council and Parliament in the reports provided for by Directive 98/44."@en1
|
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples